undamentalytics Newsletter
Sign in

Amphastar Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Amphastar Pharmaceuticals, Inc. had total assets of $1.63bn, total liabilities of $840m and shareholders' equity of $789m. It held $170m in cash against $621m of debt: net debt of $451m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents505468667266867493126156144152170224
Receivables—25233327365245667989115136144145
Inventory—7082718064691119793104106154177180
Total current assets—173198176184188220255280318378490534636631
Goodwill004444444333333
Total assets—3393893904284515145876316727421,5131,5771,6291,744
Accounts payable—2010142017312524222125313329
Deferred revenue (current)——141———————————
Total current liabilities—65636061671079011210495225174158263
Long-term debt—10434036464946467877603614620610
Total debt032505141526754588080604614621612
Total liabilities—871089598117149159183226213873845840976
Shareholders' equity233252282296329334332381402446529639732789768
Non-controlling interests and other (assets − liabilities − equity)——————324646——————
Net debt (negative = net cash)−50−21−18−15−31−14−19−20−34−46−76459462451388
Shares outstanding—39m45m45m46m47m47m47m47m48m48m48m48m46m43m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AMPH vs PCRXAMPH vs TVTXAMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amphastar Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amphastar Pharmaceuticals, Inc.